Valeant Pharmaceuticals adds prominent US investor John Paulson to board

Valeant Pharmaceuticals adds prominent US investor John Paulson to board

Valeant Pharmaceuticals adds prominent US investor John Paulson to board

(NYSE:VRX) (TSE:VRX)'s stock had its "buy" rating reissued by equities researchers at Stifel Nicolaus in a report issued on Wednesday, May 17th. They now have a $19.00 price objective on the specialty pharmaceutical company's stock. Deutsche Bank maintained it with "Hold" rating and $29.0 target in Friday, October 14 report. The original version of this piece of content can be read at Bank of America maintained Valeant Pharmaceuticals Intl Inc (NYSE:VRX) on Wednesday, September 30 with "Buy" rating. Canaccord Genuity set a $19.00 target price on Valeant Pharmaceuticals International and gave the stock a hold rating in a research report on Wednesday, February 22nd. Fmr Ltd Limited Liability Company holds 2.15 million shares or 0% of its portfolio. 14,674,829 shares of the stock traded hands. The firm's market capitalization is $4.40 billion. The firm has a 50-day moving average of $12.26 and a 200-day moving average of $12.99. Valeant Pharmaceuticals International has a 12 month low of $8.31 and a 12 month high of $32.74. Valeant Pharmaceuticals International also was the target of unusually large options trading on Friday. Stock traders bought 35,088 put options on the stock. This is an increase of 215% compared to the typical volume of 11,124 put options. (NYSE:VRX) (TSE:VRX) by 2.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 261,532 shares of the specialty pharmaceutical company's stock at the end of the first quarter. The firm had revenue of $2.11 billion during the quarter, compared to analyst estimates of $2.17 billion.

Valeant Pharmaceuticals International, a pharmaceutical and medical device company. On average, analysts expect that Valeant Pharmaceuticals International, Inc. will post $3.89 EPS for the current year. During the same period previous year, the firm posted ($1.08) EPS.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and worldwide copyright laws.

In other news, Director Schutter Richard U. De bought 20,000 shares of the firm's stock in a transaction dated Thursday, May 11th.

In the transaction dated March 14, 2017, the great number of shares acquired came courtesy the; ValueAct Capital Master Fund, added a total of 3,000,000 shares at an average price of $10.82, amounting to approximately $32,460,000.

Institutional investors now hold around $2.26 billion or 66.8% in VRX stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Synovus Financial Corporation, Georgia-based fund reported 5 shares.

A number of institutional investors have recently added to or reduced their stakes in VRX.

Valeant Pharmaceuticals International, Inc., launched on August 9, 2013, is a specialty pharmaceutical and medical device company. Finally, Fosun International Ltd raised its position in Valeant Pharmaceuticals International by 13.8% in the third quarter. ValueAct Holdings L.P. now owns 17,997,224 shares of the specialty pharmaceutical company's stock valued at $198,509,000 after buying an additional 3,002,963 shares during the period. LeJeune Puetz Investment Counsel LLC bought a new stake in Valeant Pharmaceuticals International during the fourth quarter worth approximately $123,000.

Pictet Asset Management Ltd. boosted its position in Valeant Pharmaceuticals International, Inc. It dropped, as 82 investors sold Valeant Pharmaceuticals Intl Inc shares while 87 reduced holdings.

Bnp Paribas Arbitrage has invested 0.07% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX).